Alnylam Pharmaceuticals (Alnylam Pharmaceuticals) Market Cap : $18,122 Mil (As of Apr. 27, 2024)

View and export this data going back to 2004. Start your Free Trial

What is Alnylam Pharmaceuticals Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Alnylam Pharmaceuticals's share price for the quarter that ended in Dec. 2023 was $191.41. Alnylam Pharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 126 Mil. Therefore, Alnylam Pharmaceuticals's market cap for the quarter that ended in Dec. 2023 was $24,078 Mil.

Alnylam Pharmaceuticals's quarterly market cap declined from Jun. 2023 ($23,724 Mil) to Sep. 2023 ($22,218 Mil) but then increased from Sep. 2023 ($22,218 Mil) to Dec. 2023 ($24,078 Mil).

Alnylam Pharmaceuticals's annual market cap increased from Dec. 2021 ($20,380 Mil) to Dec. 2022 ($29,451 Mil) but then declined from Dec. 2022 ($29,451 Mil) to Dec. 2023 ($24,078 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Alnylam Pharmaceuticals's Enterprise Value for Today is $17,038 Mil.

Alnylam Pharmaceuticals Market Cap Historical Data

The historical data trend for Alnylam Pharmaceuticals's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alnylam Pharmaceuticals Market Cap Chart

Alnylam Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Market Cap

Get a 7-Day Free Trial

12,920.69

15,132.02

20,380.46

29,450.78

24,078.23

Alnylam Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Market Cap	Get a 7-Day Free Trial															29,450.78	24,887.96	23,723.70	22,217.90	24,078.23

Competitive Comparison of Alnylam Pharmaceuticals's Market Cap

For the Biotechnology subindustry, Alnylam Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alnylam Pharmaceuticals's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Market Cap distribution charts can be found below:

* The bar in red indicates where Alnylam Pharmaceuticals's Market Cap falls into.

Alnylam Pharmaceuticals Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Alnylam Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )	=	Share Price (A: Dec. 2023 )	*	Shares Outstanding (EOP) (A: Dec. 2023 )
	=	$191.41	*	125.794
	=	$24,078

Alnylam Pharmaceuticals's Market Cap for the quarter that ended in Dec. 2023 is calculated as

Market Cap (Q: Dec. 2023 )	=	Share Price (Q: Dec. 2023 )	*	Shares Outstanding (EOP) (Q: Dec. 2023 )
	=	$191.41	*	125.794
	=	$24,078

Alnylam Pharmaceuticals (NAS:ALNY) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

Alnylam Pharmaceuticals Market Cap Related Terms

Thank you for viewing the detailed overview of Alnylam Pharmaceuticals's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

Alnylam Pharmaceuticals (Alnylam Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alnylam Pharmaceuticals Inc (NAS:ALNY) » Definitions » Market Cap

Comparable Companies

Traded in Other Exchanges

ALNY:Mexico DUL:Germany DUL:Germany

Address

675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142

Website

https://www.alnylam.com

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Executives

Michael W Bonney	director	65 HAYDEN AVE, LEXINGTON MA 02421
Pushkal Garg	officer: CMO & EVP Dev & Med Affairs	C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Akshay Vaishnaw	officer: SVP, Clinical Research	300 THIRD STREET, CAMBRIDGE MA 02139
Yvonne Greenstreet	officer: EVP, Chief Commercial Officer	PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, PARSIPPANY NJ 07054
Jeffrey V. Poulton	officer: Chief Financial Officer	300 THIRD STREET, CAMBRIDGE MA 02142
Tolga Tanguler	officer: EVP, Chief Commercial Officer	675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE MA 02142
Indrani Lall Franchini	officer: EVP, CLO & Secretary	C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
Peter N Kellogg	director	MERCK & CO., INC, ONE MERCK DRIVE., P.O. BOX 100, WHITEHOUSE STATION NJ 08889-0100
Carolyn R Bertozzi	director	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Dennis A Ausiello	director	PFIZER INC ATTN CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Charles Elliott Sigal	director	32 BREARLY ROAD, PRINCETON NJ 08540
Phillip A Sharp	director	BIOGEN INC LEGAL DEPARTMENT, 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
John Maraganore	director, officer: President and CEO	75 SIDNEY ST, CAMBRIDGE MA 02139
Laurie Keating	officer: SVP,GC & Secretary	300 THIRD STREET, CAMBRIDGE MA 02142
Steven M Paul	director	C/O ELI LITTY & CO, LIIY CORPORATE CENTER DC 1093, INDIANAPOLIS IN 46285